Miltenyi Biotec established in 1989 by Stefan Miltenyi, stands as a leading private company. Over nearly three decades, Miltenyi Biotec has been pivotal in conceiving and integrating cutting-edge products that fuel the progress of biomedical research and drive advancements in cell and gene therapy. Our team comprises over 3,000 dedicated individuals,, including scientists engineers, physicians, support specialists, and marketers, all united in our mission to enhance scientific knowledge and positively impact human lives. Across the years, we’ve pioneered innovative technologies spanning for Sample Preparation, Cell Separation, Cell Culture, Flow Cytometry, Imaging & Cell & Gene therapy. A core focus lies in orchestrating and overseeing clinical studies to evaluate the therapeutic efficacy of Miltenyi Biotec’s clinical products. These studies encompass a wide spectrum, including regenerative medicine, stem cell therapy, hemato-oncological, infectious diseases and cancer immunotherapy. Working with esteemed professionals globally, we conduct trials ranging from safety/feasibility (phase I/II) to pivotal stage (phase III) and post-market surveillance studies. Additionally, our products are actively used in independent academic trials across the aforementioned therapeutic areas.